Last-Resort drug access opens for rare lung cancer patients
NCT ID NCT06841874
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 26 times
Summary
This program offers taletrectinib to adults with advanced or spreading ROS1-positive non-small cell lung cancer who cannot use approved treatments or join ongoing studies. Participants must have a ROS1 gene fusion and adequate organ function. The goal is to provide potential benefit when no other options are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.